Cargando…
Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medicat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649612/ https://www.ncbi.nlm.nih.gov/pubmed/37949625 http://dx.doi.org/10.1136/bmjopen-2023-075840 |
_version_ | 1785135592388952064 |
---|---|
author | Lauffenburger, Julie C Tesfaye, Helen Solomon, Daniel H Antman, Elliott M Glynn, Robert J Lee, Su Been Tong, Angela Choudhry, Niteesh K |
author_facet | Lauffenburger, Julie C Tesfaye, Helen Solomon, Daniel H Antman, Elliott M Glynn, Robert J Lee, Su Been Tong, Angela Choudhry, Niteesh K |
author_sort | Lauffenburger, Julie C |
collection | PubMed |
description | OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medication properties thought to be influential translate into lower objectively-measured adherence. DESIGN: Retrospective cohort study. SETTING: US nationwide commercial claims database, 2016–2019. PARTICIPANTS: Among patients initiating first-line hypertension, diabetes or hyperlipidaemia treatment based on clinical guidelines, we measured pill size, shape, colour and flavouring, number of pills/day and fixed-dose combination status as properties. OUTCOME MEASURES: Outcomes included discontinuation after the first fill (ie, never filling again over a minimum of 1-year follow-up) and long-term non-adherence (1-year proportion of days covered <0.80). We estimated associations between each property and outcomes, by therapeutic class (eg, statins), with multivariable logistic regression. RESULTS: Across 604 323 patients, 14.6% discontinued after filling once (ie, were non-persistent), and 54.0% were non-adherent over 1-year follow-up. Large pill size was associated with non-adherence, except for thiazides (eg, metformin adjusted OR (aOR): 1.12, 95% CI: 1.06 to 1.18). Greater pill burden was associated with a higher risk of non-adherence across all classes (eg, metformin aOR: 1.58, 95% CI: 1.53 to 1.64 for two pills/day). Taking less than one pill/day was also associated with higher risk of non-adherence and non-persistence (eg, non-persistence statin aOR: 1.29, 95% CI: 1.20 to 1.38). Pill shape, colour, flavouring and combination status were associated with mixed effects across classes. CONCLUSIONS: Pill burden and pill size are key properties affecting adherence for almost all classes; others, like size and combination, could modestly affect medication adherence. Clinical interventions could screen patients for potential intolerance to medication and potentially implement more convenient dosing schedules. |
format | Online Article Text |
id | pubmed-10649612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-106496122023-11-10 Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA Lauffenburger, Julie C Tesfaye, Helen Solomon, Daniel H Antman, Elliott M Glynn, Robert J Lee, Su Been Tong, Angela Choudhry, Niteesh K BMJ Open Public Health OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medication properties thought to be influential translate into lower objectively-measured adherence. DESIGN: Retrospective cohort study. SETTING: US nationwide commercial claims database, 2016–2019. PARTICIPANTS: Among patients initiating first-line hypertension, diabetes or hyperlipidaemia treatment based on clinical guidelines, we measured pill size, shape, colour and flavouring, number of pills/day and fixed-dose combination status as properties. OUTCOME MEASURES: Outcomes included discontinuation after the first fill (ie, never filling again over a minimum of 1-year follow-up) and long-term non-adherence (1-year proportion of days covered <0.80). We estimated associations between each property and outcomes, by therapeutic class (eg, statins), with multivariable logistic regression. RESULTS: Across 604 323 patients, 14.6% discontinued after filling once (ie, were non-persistent), and 54.0% were non-adherent over 1-year follow-up. Large pill size was associated with non-adherence, except for thiazides (eg, metformin adjusted OR (aOR): 1.12, 95% CI: 1.06 to 1.18). Greater pill burden was associated with a higher risk of non-adherence across all classes (eg, metformin aOR: 1.58, 95% CI: 1.53 to 1.64 for two pills/day). Taking less than one pill/day was also associated with higher risk of non-adherence and non-persistence (eg, non-persistence statin aOR: 1.29, 95% CI: 1.20 to 1.38). Pill shape, colour, flavouring and combination status were associated with mixed effects across classes. CONCLUSIONS: Pill burden and pill size are key properties affecting adherence for almost all classes; others, like size and combination, could modestly affect medication adherence. Clinical interventions could screen patients for potential intolerance to medication and potentially implement more convenient dosing schedules. BMJ Publishing Group 2023-11-10 /pmc/articles/PMC10649612/ /pubmed/37949625 http://dx.doi.org/10.1136/bmjopen-2023-075840 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Public Health Lauffenburger, Julie C Tesfaye, Helen Solomon, Daniel H Antman, Elliott M Glynn, Robert J Lee, Su Been Tong, Angela Choudhry, Niteesh K Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title | Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title_full | Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title_fullStr | Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title_full_unstemmed | Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title_short | Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA |
title_sort | investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the usa |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649612/ https://www.ncbi.nlm.nih.gov/pubmed/37949625 http://dx.doi.org/10.1136/bmjopen-2023-075840 |
work_keys_str_mv | AT lauffenburgerjuliec investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT tesfayehelen investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT solomondanielh investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT antmanelliottm investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT glynnrobertj investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT leesubeen investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT tongangela investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa AT choudhryniteeshk investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa |